The last time I wrote about Viridian Therapeutics, Inc. (VRDN) it was in a Seeking Alpha article entitled “Viridian: Despite Drop, Advancement Towards Phase 3 continues.” At that time, I noted that ...
Viridian Therapeutics (NASDAQ:VRDN) appears to be ending on a high note in 2024, because it just reported positive results from its phase 3 THRIVE-2 study using its anti-IGF-1R drug veligrotug ...
On Wednesday, H.C. Wainwright maintained its Buy rating and $27.00 price target for Viridian Therapeutics (NASDAQ:VRDN), following the company's announcement of positive results from its THRIVE-1 ...
- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52 - - Veligrotug recently received Breakthrough Therapy Designation (BTD ...
Shares of Viridian Therapeutics Inc. (NASDAQ:VRDN) were trading at $16.06, up $1.87, or 13% on positive top-line data from the Thrive phase III trial of VRDN-001, or veligrotug, an intravenously ...
Cuireadh roinnt torthaí i bhfolach toisc go bhféadfadh siad a bheith dorochtana duit
Taispeáin torthaí dorochtana
Aiseolas